Rep. Kevin Hern Sells Shares of Danaher Corporation (NYSE:DHR)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Danaher Corporation (NYSE:DHR). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Danaher stock on September 2nd. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

  • Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
  • Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
  • Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
  • Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
  • Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
  • Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
  • Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
  • Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
  • Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
  • Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Danaher Price Performance

NYSE:DHR traded down $3.37 during mid-day trading on Tuesday, hitting $223.96. The company’s stock had a trading volume of 550,667 shares, compared to its average volume of 4,451,113. The company has a market capitalization of $157.44 billion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 2.80 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a fifty day moving average of $206.57 and a 200-day moving average of $192.90.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.77 EPS. As a group, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DHR. The Goldman Sachs Group increased their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. TD Cowen dropped their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Evercore restated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Finally, UBS Group started coverage on Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $230.23.

Get Our Latest Analysis on Danaher

Institutional Investors Weigh In On Danaher

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Danaher during the 2nd quarter worth $10,492,520,000. Norges Bank acquired a new stake in shares of Danaher during the fourth quarter worth $2,177,106,000. Jupiter Topco LLC bought a new stake in Danaher in the second quarter valued at about $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher in the second quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher in the second quarter valued at about $993,846,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Danaher Company Profile

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Featured Articles

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.